News - Abzena

Filter by year

Filter by topic

Information on Abzena’s Response to COVID-19

This page will remain up to date on Abzena’s response to COVID-19 Last updated 09:30 GMT 25th March 2020 To Our Valued Partner, As public announcements are made and countries move to “non-life sustaining” business closures, “essential critical infrastructure” and “key workers in a critical sector” definitions, we want to re-assure you that we are […] Read more

Information on Abzena’s Response to COVID-19

This page will remain up to date on Abzena’s response to COVID-19 Last updated 15:00 GMT 17th March 2020 The COVID-19 pandemic is a global public health issue of concern to all. I want to update you on our detailed efforts to ensure the health and well-being of our employees, as well as our business […] Read more

Spotlight on Abzena’s Developability Platform during Antibody Engineering & Therapeutics 2019

New service reduces the risk, expenditure and time required for the later stages of antibody development Cambridge, UK, 9 December 2019 – Abzena is showcasing its new Developability Service, enabling biotechnology and pharmaceutical companies to improve lead selection and de-risk cell line development, at Antibody Engineering & Therapeutics 2019 being held 9–13 December, on Booth […] Read more

Abzena Showcases Discovery and Developability Services at PEGS Europe 2019

Bespoke approach generates high affinity antibodies and selects lead candidates with the strongest chances of success in the clinic Cambridge, UK, 18 November 2019 – Abzena is showcasing its Discovery and Developability Services, enabling biopharmaceutical companies to generate high affinity antibodies and select lead candidates with the highest chances of clinical success at the 11th Annual Protein […] Read more

Sonnet BioTherapeutics selects Abzena as clinical stage manufacturing partner for its IL-12-FHAB cytokine-derived therapeutic candidate

PRINCETON, NJ and San Diego, CA, USA 22 October 2019 – Sonnet BioTherapeutics Inc., a clinical stage biopharmaceutical developing innovative targeted biologic drugs, announced today that it has selected Abzena as its manufacturing partner for SON-1010, an IL-12-FHAB cytokine, in preparation for clinical development. SON-1010 uses Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology that leverages […] Read more

Abzena Names Kimball Hall as Chief Operating Officer

Abzena announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive leadership team. Ms. Hall will focus on the growth of Abzena as the leading Partner Research Organization (PRO) for outsourced integrated gene to GMP services for large molecules and antibody drug conjugates.  She joins Abzena from Genentech, a […] Read more

Abzena offers integrated clinical translation of biologics with launch of ADC Cascade and Biologics Cascade

Cambridge, UK 07 October 2019 – Abzena, the leading biologics target to GMP Partner Research Organisation, announced it has augmented its antibody drug conjugation (ADC) and biologics (including mono and bispecific antibodies) development services with the launch of ADC Cascade and Biologics Cascade. These ex-vivo platform approaches allow efficacy and safety studies against clinically characterized […] Read more

Abzena announces successful technical transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) technology to enable use in client projects

San Diego, USA July 2019 – Abzena, the global partner research organization, announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody conjugation) and HydraSpace™ (highly polar spacer). Familiarity with these Antibody-Drug Conjugate (ADC) technologies adds to Abzena’s leadership in process development and GMP manufacturing of ADC […] Read more

Abzena expands leadership team with Andrew Kraus as Chief Technology Officer and Philip Payne as Chief Commercial Officer

San Diego, USA , 21 June 2019 – Abzena, the leading global biologics and ADC target partner research organization, announced it has appointed Andrew Kraus as Chief Technology Officer (CTO) and Philip Payne as Chief Commercial Officer (CCO). As CTO Mr. Kraus will implement advanced technology solutions to further enhance data integrity controls, regulatory compliance […] Read more

Abzena announces 14-month cell line to phase 1 GMP service and appointment of Shahram Katousian as Head of biologics manufacturing

San Diego, USA, 3 June 2019 – Abzena, the leading biotherapeutics target to GMP partner research organization (PRO) announced an accelerated program to IND.  This reduces timeline from stable pool to GMP down to 14 months. The timeline is achieved by use of single project team with experienced leadership, overlapping of operational activities, internal technology transfer […] Read more

Interested in our services? Get In Touch